ATE313803T1 - In vitro screening nach liganden des östrogenrezeptors - Google Patents
In vitro screening nach liganden des östrogenrezeptorsInfo
- Publication number
- ATE313803T1 ATE313803T1 AT01126336T AT01126336T ATE313803T1 AT E313803 T1 ATE313803 T1 AT E313803T1 AT 01126336 T AT01126336 T AT 01126336T AT 01126336 T AT01126336 T AT 01126336T AT E313803 T1 ATE313803 T1 AT E313803T1
- Authority
- AT
- Austria
- Prior art keywords
- ligand
- src
- assay system
- ligands
- vitro screening
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 7
- 238000012216 screening Methods 0.000 title abstract 3
- 238000000338 in vitro Methods 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 abstract 3
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 abstract 2
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 108700008625 Reporter Genes Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000007824 enzymatic assay Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126336A EP1310799B1 (de) | 2001-11-07 | 2001-11-07 | In vitro Screening nach Liganden des Östrogenrezeptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE313803T1 true ATE313803T1 (de) | 2006-01-15 |
Family
ID=8179169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01126336T ATE313803T1 (de) | 2001-11-07 | 2001-11-07 | In vitro screening nach liganden des östrogenrezeptors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7166438B2 (de) |
| EP (1) | EP1310799B1 (de) |
| JP (1) | JP3754647B2 (de) |
| AT (1) | ATE313803T1 (de) |
| DE (1) | DE60116109T2 (de) |
| ES (1) | ES2253318T3 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658912B2 (en) * | 2003-06-20 | 2010-02-09 | University Of Massachusetts | Spatial evolution of neural activity |
| WO2006065968A2 (en) * | 2004-12-17 | 2006-06-22 | Wyeth | The uses of estrogen beta agonists to treat cognitive diseases |
| US8320649B2 (en) | 2006-05-25 | 2012-11-27 | Elminda Ltd. | Neuropsychological spatiotemporal pattern recognition |
| WO2009069135A2 (en) * | 2007-11-29 | 2009-06-04 | Elminda Ltd. | System and method for neural modeling of neurophysiological data |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2301143A1 (en) | 1997-09-04 | 1999-03-11 | The Regents Of The University Of California | Differential ligand activation of estrogen receptors er.alpha. and er.beta. at ap1 sites |
| EP1021462A4 (de) | 1997-10-07 | 2005-04-13 | Merck & Co Inc | Test für kernrezeptor-liganden unter verwendung von fret |
| JP2002503811A (ja) * | 1998-02-12 | 2002-02-05 | プロリフィクス リミテッド | サイクリンｄ１とステロイド受容体コアクチベーターとの相互作用、およびアッセイにおけるその使用 |
| WO1999042108A1 (de) * | 1998-02-20 | 1999-08-26 | Jenapharm Gmbh & Co. Kg | Pharmazeutische präparate zur gezielten substitution des estrogenmangels im zentralnervensystem |
| AU1344300A (en) * | 1998-11-04 | 2000-05-22 | Board Of Trustees Of The University Of Illinois, The | Repressor of estrogen receptor activity |
| WO2000037681A1 (en) | 1998-12-18 | 2000-06-29 | American Home Products Corporation | BIOASSAY FOR IDENTIFYING ESTROGEN RECEPTOR-β/α SELECTIVE MODULATORS |
-
2001
- 2001-11-07 EP EP01126336A patent/EP1310799B1/de not_active Expired - Lifetime
- 2001-11-07 AT AT01126336T patent/ATE313803T1/de not_active IP Right Cessation
- 2001-11-07 ES ES01126336T patent/ES2253318T3/es not_active Expired - Lifetime
- 2001-11-07 DE DE60116109T patent/DE60116109T2/de not_active Expired - Fee Related
- 2001-11-20 US US09/989,952 patent/US7166438B2/en not_active Expired - Fee Related
- 2001-12-07 JP JP2001374287A patent/JP3754647B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60116109D1 (de) | 2006-01-26 |
| EP1310799B1 (de) | 2005-12-21 |
| US20030087303A1 (en) | 2003-05-08 |
| US7166438B2 (en) | 2007-01-23 |
| ES2253318T3 (es) | 2006-06-01 |
| EP1310799A1 (de) | 2003-05-14 |
| JP3754647B2 (ja) | 2006-03-15 |
| JP2003144192A (ja) | 2003-05-20 |
| DE60116109T2 (de) | 2006-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Siever et al. | The boundaries of schizophrenia | |
| ATE434975T1 (de) | Vorrichtung und verfahren zur repositionierung von patienten | |
| WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
| EP1754707A3 (de) | Multicyclische Verbindungen und deren Verwendung als Inhibitoren der PARP, VEGFR2 und MLK3 Enzyme | |
| BR0213958A (pt) | Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1 | |
| BR0011838B1 (pt) | elemento de sela e estrutura de misturador estático. | |
| ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
| HUP0300841A2 (hu) | Agonista aktivitású anti-trkC monoklonális antitestek | |
| WO2004096148A3 (en) | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof | |
| MA27766A1 (fr) | Ligands de recepteurs de cannabinoides et leurs utilisations | |
| AP2002002620A0 (en) | Substituted arylpyrazines | |
| MA31779B1 (fr) | Activateurs de glucokinase | |
| ITBO20020620A1 (it) | Condotto multi-canale bioriassorbibile di rigenerazione del nervo e processo per preparare il medesimo. | |
| EA201070169A1 (ru) | 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы | |
| DE602004026767D1 (de) | Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen | |
| TW200510373A (en) | Substituted quinolin-4-ylamine analogues | |
| EE04961B1 (et) | N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis | |
| DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
| ATE313803T1 (de) | In vitro screening nach liganden des östrogenrezeptors | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| ATE405585T1 (de) | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen | |
| ATE425752T1 (de) | Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| WO2006071538A3 (en) | Substituted biaryl analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1310799 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |